PEDIATRICS Vol. 104 No. 2 August 1999, pp. 258-262
Relationship Among Genotype, Biochemical Phenotype, and Cognitive Performance in Females With Phenylalanine Hydroxylase Deficiency: Report From the Maternal Phenylketonuria Collaborative Study
Received Jul 27, 1998; accepted Dec 21, 1998.
,
,
From the * John F. Kennedy Institute, Glostrup, Denmark;
Children's Hospital, Division of Medical Genetics and the
University of Southern California, Los Angeles, California; § Hospital
for Sick Children, Toronto, Canada; Children's Hospital and
Department of Pediatrics, Harvard Medical School, Boston,
Massachusetts; ¶ University of Texas Medical Branch, Children's
Hospital, Galveston, Texas; # University of Tübingen, Reutlingen,
Germany; and ** National Institute of Child Health and Human
Development, Bethesda, Maryland.
Objective. To examine the relationship of phenylalanine hydroxylase (PAH) genotypes to biochemical phenotype and cognitive development in maternal phenylketonuria (PKU).
Methodology. PAH gene mutations were examined in 222 hyperphenylalaninemic females enrolled in the Maternal PKU Collaborative Study (MPKUCS). A total of 84 different mutations were detected, and complete genotype was obtained in 199 individuals. Based on previous knowledge about mutation-phenotype associations, 78 of the mutations could be assigned to one of four classes of severity (severe PKU, moderate PKU, mild PKU, and mild hyperphenylalaninemia [MHP]). Then, 189 MPKUCS subjects were grouped according to the various combinations of mutation classifications. The sample sizes were large enough for statistical testing in four groups with at least one mutation that completely abolishes enzyme activity. These patients are considered functionally hemizygous.
Results. The biochemical phenotype predicted from the genotype in functionally hemizygous patients was related significantly to the assigned phenylalanine level. Cognitive performance (IQ) was also significantly related to genotype. The IQ of PAH-deficient mothers with a severe PKU mutation in combination with a MHP mutation or a mild PKU mutation was 99 and 96, respectively, whereas the IQ of PKU mothers with two severe PKU mutations or with one severe and one moderate PKU mutation was 83 and 84, respectively. Of the patients with PKU, 92% had been treated during childhood. Those who were untreated or treated late had lower than average IQ scores for their group of mutation combinations. Females with moderate or mild PKU who were treated early and treated for >6 years showed IQ scores 10 points above average for their group.
Conclusions. The reproductive outcome in maternal phenylketonuria is dependent on prenatal metabolic control and postnatal environmental circumstances. Both factors depend on the intellectual resources of the mother with PKU. The significant relationship among genotype, biochemical phenotype, and cognitive performance observed in the present study is of importance for the development of an optimal strategy for future treatment of females with PKU who plan pregnancy. Key words: phenylalanine hydroxylase, phenylketonuria, genotype-phenotype correlation, hyperphenylalaninemia, maternal phenylketonuria.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Koch, W. Hanley, H. Levy, K. Matalon, R. Matalon, B. Rouse, F. Trefz, F. Guttler, C. Azen, L. Platt, et al. The Maternal Phenylketonuria International Study: 1984-2002 Pediatrics, December 1, 2003; 112(6): 1523 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guttler, C. Azen, P. Guldberg, A. Romstad, W. B. Hanley, H. L. Levy, R. Matalon, B. M. Rouse, F. Trefz, F. de la Cruz, et al. Impact of the Phenylalanine Hydroxylase Gene on Maternal Phenylketonuria Outcome Pediatrics, December 1, 2003; 112(6): 1530 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Waisbren and C. Azen Cognitive and Behavioral Development in Maternal Phenylketonuria Offspring Pediatrics, December 1, 2003; 112(6): 1544 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Levy, S. E. Waisbren, F. Guttler, W. B. Hanley, R. Matalon, B. Rouse, F. K. Trefz, F. de la Cruz, C. G. Azen, and R. Koch Pregnancy Experiences in the Woman With Mild Hyperphenylalaninemia Pediatrics, December 1, 2003; 112(6): 1548 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T.R. Clarke The Maternal Phenylketonuria Project: A Summary of Progress and Challenges for the Future Pediatrics, December 1, 2003; 112(6): 1584 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Institutes of Health Consensus Developmen National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16-18, 2000 Pediatrics, October 1, 2001; 108(4): 972 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bonafe, N. Blau, A. P. Burlina, A. Romstad, F. Guttler, and A. B. Burlina Treatable neurotransmitter deficiency in mild phenylketonuria Neurology, September 11, 2001; 57(5): 908 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B Acosta, K. Matalon, L. Castiglioni, F. J Rohr, E. Wenz, V. Austin, and C. Azen Intake of major nutrients by women in the Maternal Phenylketonuria (MPKU) Study and effects on plasma phenylalanine concentrations Am. J. Clinical Nutrition, April 1, 2001; 73(4): 792 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Koch, R. Moats, F. Guttler, P. Guldberg, and M. Nelson Jr. Blood-Brain Phenylalanine Relationships in Persons With Phenylketonuria Pediatrics, November 1, 2000; 106(5): 1093 - 1096. [Abstract] [Full Text]
|
|
|
|
|
|
R. Koch and F. Güttler Benefits of Mutation Analysis and Examination of Brain Phenylalanine Levels in the Management of Phenylketonuria Pediatrics, November 1, 2000; 106(5): 1136 - 1136. [Full Text]
|
|
